Apellis Pharmaceuticals (APLS) News Today $19.47 -0.57 (-2.84%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$19.97 +0.50 (+2.57%) As of 07/18/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Apellis Pharmaceuticals Down Today?Toggle Visibility of Why Is Apellis Pharmaceuticals Down Today?Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its shares rise today following a wave of bullish analyst revisions alongside mixed insider activity. Here’s what moved the stock: Positive Sentiment: Robert W. Baird raised its price target on APLS to $50.00 from $47.00 and maintained an “outperform” rating, implying roughly 157% upside. Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $50.00 Positive Sentiment: Wedbush lifted its FY2025 EPS forecast for APLS to a loss of ($0.16) per share from ($0.22), signaling an expectation of narrower losses. Wedbush Has Bullish Outlook for APLS FY2025 Earnings Positive Sentiment: Wedbush also raised its Q3 2025 EPS estimate to $1.41 from $1.35, reflecting stronger near-term profitability trends. Equities Analysts Issue Forecasts for APLS Q3 Earnings Neutral Sentiment: Benzinga’s deep dive into 15 recent analyst ratings shows a consensus “moderate buy” stance on APLS, with target prices clustered in the high-$30s. APLS: A Deep Dive Into Analyst Perspectives Negative Sentiment: CEO Cedric Francois sold 1,900 shares of APLS at an average price of $20.09, modestly trimming his stake. Cedric Francois Sells 1,900 Shares of Apellis Pharmaceuticals Stock Posted 14h agoAI Generated. May Contain Errors. APLS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $97,750.00 in Stock1 hour ago | insidertrades.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Holdings Decreased by Jennison Associates LLC1 hour ago | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Cwm LLC3 hours ago | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $24.00July 19 at 2:36 AM | americanbankingnews.com3APLS : Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives...July 18 at 9:40 AM | benzinga.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $50.00July 18 at 9:31 AM | marketbeat.comWedbush Has Bullish Outlook for APLS FY2025 EarningsJuly 18 at 4:31 AM | americanbankingnews.comEquities Analysts Issue Forecasts for APLS Q3 EarningsJuly 18 at 2:39 AM | americanbankingnews.comCedric Francois Sells 1,900 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockJuly 17 at 6:53 AM | insidertrades.comWedbush Research Analysts Boost Earnings Estimates for APLSJuly 17 at 6:52 AM | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $38,171.00 in StockJuly 16 at 7:18 PM | marketbeat.comCedric Francois Sells 137,465 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockJuly 16 at 6:47 PM | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $24.00 Price Target at Bank of AmericaJuly 16 at 8:37 AM | marketbeat.comWedbush Lifts Earnings Estimates for Apellis PharmaceuticalsJuly 16 at 6:46 AM | marketbeat.comEdgestream Partners L.P. Boosts Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)July 16 at 5:16 AM | marketbeat.comApellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific MeetingJuly 15, 2025 | globenewswire.comApellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300MJuly 9, 2025 | finance.yahoo.comKBC Group NV Sells 100,437 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)July 9, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 9, 2025 | marketbeat.comMorgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold RatingJuly 6, 2025 | msn.comAnalysts Set Expectations for APLS FY2025 EarningsJuly 4, 2025 | marketbeat.comWedbush Equities Analysts Raise Earnings Estimates for APLSJuly 4, 2025 | marketbeat.comWilliam Blair Analysts Lift Earnings Estimates for APLSJuly 4, 2025 | marketbeat.comApellis Pharmaceuticals Secures $275M Royalty Buy-Down DealJuly 3, 2025 | theglobeandmail.comWedbush Has Bearish Estimate for APLS FY2028 EarningsJuly 3, 2025 | marketbeat.comWilliam Blair Has Negative Forecast for APLS Q4 EarningsJuly 3, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market MispricingJuly 2, 2025 | insidermonkey.com5APLS : What 13 Analyst Ratings Have To Say About Apellis PharmaceuticalsJuly 2, 2025 | benzinga.comMorgan Stanley Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) StockJuly 2, 2025 | marketbeat.comZacks Research Issues Optimistic Forecast for APLS EarningsJuly 2, 2025 | marketbeat.comApellis stock surges after Sobi $300 million royalty dealJuly 1, 2025 | msn.comApellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)July 1, 2025 | finance.yahoo.comApellis signs royalty purchase deal with Sobi for AspaveliJuly 1, 2025 | msn.comSobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)July 1, 2025 | prnewswire.comApellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)July 1, 2025 | globenewswire.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Wealth Enhancement Advisory Services LLCJuly 1, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (APLS) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comApellis Pharmaceuticals Inc News (APLS) - Investing.comJune 24, 2025 | investing.comDavid O. Watson Sells 5,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockJune 19, 2025 | insidertrades.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assenagon Asset Management S.A.June 18, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.4% - What's Next?June 16, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 14, 2025 | marketbeat.comSG Americas Securities LLC Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)June 12, 2025 | marketbeat.comPallas Capital Advisors LLC Grows Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)June 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for APLS FY2026 EarningsJune 10, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Merit Financial Group LLCJune 9, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)June 9, 2025 | marketbeat.comApellis, Sobi present data from open-label period of Phase 3 VALIANT studyJune 7, 2025 | finance.yahoo.comHennion & Walsh Asset Management Inc. Grows Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)June 7, 2025 | marketbeat.comApellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGNJune 6, 2025 | globenewswire.com Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.600.57▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼269▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BBIO News VRNA News BPMC News ROIV News ELAN News RGC News LEGN News RVMD News GRFS News TGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts